Sign up USA
Proactive Investors - Run By Investors For Investors

Feedback receives long-awaited CE mark for its TexRAD Lung software

TexRAD is essentially a very smart piece of software that analyses medical images to reveal features that are not always evident to the human eye
lung x-ray
Medical devices are required to have a CE mark before they can legally be sold in the European Union

Specialist medical imaging group Feedback plc (LON:FDBK) has finally received a CE mark for its TexRAD Lung technology.

The company had previously expected the CE mark by the end of May but several enhancements that have improved the performance of TexRAD Lung led to a delay.

READ: Feedback to squeeze in more enhancements to TexRAD Lung ahead of CE mark ruling

Distilled to its basics, TexRAD is a very smart piece of software that analyses medical images to reveal features that are not always evident to the human eye.

This particular version of the product will help doctors diagnose and treat people with lung cancer, the most common and most deadly form of the disease.

By analysing “texture features” in CT scans, TexRAD's quantitative imaging capabilities provide clinicians with additional information to make better decisions in order to improve patient outcomes.

The award of the CE mark means Feedback can now sell TexRAD Lung to hospitals, satisfying the quality, safety and performance standards required for medical devices in the European Union.

Next step, liver cancer and COPD

"TexRAD Lung is our first TexRAD product with a CE mark which represents a significant accomplishment,” said chairman Alastair Riddell.

“This development will expedite TexRAD's clinical use in the treatment of lung cancer across the EU, expand its market presence and support the Company's ongoing commercial discussions for the technology.

"We expect that the rigorous regulatory review required for the CE mark will pave the way for TexRAD's clinical use worldwide and we are now investigating the clinical application of TexRAD in liver cancer and chronic obstructive pulmonary disease (COPD).

He added: “By arming clinicians with disease-specific tools, we believe this technology has the potential to transform radiological decision making.”

View full FDBK profile View Profile

Feedback plc Timeline

November 07 2017

Related Articles

Dementia ward
January 15 2018
It's not exactly what the Silicon Valley companies would call a "pivot"; it's more of an acknowledgement that lighting solutions have to make full use of the available technology
Hydrogen refuelling
April 05 2018
As the move towards alternative fuels for vehicles gathers pace, news last month of the opening of the first 'under the canopy' hydrogen refuelling station at Beaconsfield Services on the M40 deserved a bit of a fanfare
Medical Scan
November 20 2017
The CE mark will enable Feedback to market not just to scientists, but radiologists everywhere, which should lead to a marked expansion in sales
Copyright ©, 2018. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use